The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
Medgadget today highlighted the SQUIGGLE RV micromotor, a 2.8 mm wide motor that has potential medical applications spanning robotic surgical devises, endoscopes, implantable devices, drug delivery, microfluidics and others:
See link.
(See also the MedMarket Diligence report on Micro/Nanomedicine.)
bookmark to
The European market for drug-eluting stents is demonstrating its maturity in terms of numbers of competitors, the upward sales growth driven by increasing unit sales rather than premium pricing and other considerations.
Source: MedMarket Diligence, LLC; Report #C245
This illustrates the challenge for manufacturers to differentiate their products and pursue innovations that can command premium pricing, a [...]
Until the advent of coronary stents, patients with cardiovascular blockages had little choice but to either keep a close eye on their disease (“watchful waiting” with or without accompanying pharmaceutical therapy) or undergo coronary artery bypass grafting (CABG). When angioplasty was developed by Andreas Gruentzig in 1977, patients were presented with the option to undergo [...]
The continued evolution of medical technologies is making it increasingly difficult, almost moot, to distinguish a medical device from other therapeutics. In Science Translational Medicine November 30, 2009, Harvard scientists report on the use of a polymer disc that stimulates an immune response that in turn shrinks tumors:
In a new approach to fighting cancer, scientists [...]
The level of investment in medical technology has been erratic of late, with July and August financings each totaling in excess of $400 million, while October financings barely crossed $200 million (and would have been much less if not for a $40 million by Direct Flow Medical and $55 million by TransEnterix). See the trend. [...]
A steady rate of technology development in coronary stents, producing an equally steady stream of new stent market introductions, is focused on expanding aggregate stent caseload (through penetration of what would otherwise be coronary artery bypass caseload) or shifting the balance even further toward concentration of stents sales to the drug-eluting stent (DES) variety. While [...]
Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years.
The local market forces dictating these differences include:
Regulatory timelines in one market [...]
The global market for stents in the treatment coronary artery disease, while dominated by drug-eluting stents, continues to also be comprised of a diversity of stent technologies. The market is evolving steadily as manufacturers aggressively seek optimal anti-restenosis, characterized by the goal of low rates of repeat revascularization.
As with many medical technologies, prices, availability in [...]
PRLog (Press Release) – Sep 09, 2009 – The global market for coronary stents is owned largely by drug-eluting stents (DES), but the size of the patient pool, the drive for lowered cost, ever-increased efficacy and less trauma are spawning the development of multiple new technologies in coronary stents and competitive anti-restenosis technologies. The global [...]
Contact:
